Morgan Stanley
ANAB icon

Morgan Stanley’s AnaptysBio ANAB Stock Holding History

Morgan Stanley’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.4M Sell
257,091
-736,814
-74% -$44.7M ﹤0.01% 3222
2026
Q1 		$55.1M Sell
993,905
-40,657
-4% -$2.19M ﹤0.01% 2001
2025
Q4 		$50.2M Sell
1,034,562
-521,696
-34% -$20.3M ﹤0.01% 2075
2025
Q3 		$47.7M Sell
1,556,258
-313,582
-17% -$7.2M ﹤0.01% 2052
2025
Q2 		$41.5M Buy
1,869,840
+1,365,204
+271% +$28.6M ﹤0.01% 2103
2025
Q1 		$9.38M Buy
504,636
+288,719
+134% +$4.82M ﹤0.01% 3390
2024
Q4 		$2.86M Buy
215,917
+38,535
+22% +$933K ﹤0.01% 4438
2024
Q3 		$5.94M Buy
177,382
+85,614
+93% +$2.92M ﹤0.01% 3837
2024
Q2 		$2.3M Sell
91,768
-544,346
-86% -$12.7M ﹤0.01% 4470
2024
Q1 		$14.3M Buy
636,114
+34,082
+6% +$807K ﹤0.01% 3029
2023
Q4 		$12.9M Buy
602,032
+521,045
+643% +$8.99M ﹤0.01% 3115
2023
Q3 		$1.45M Buy
80,987
+9,369
+13% +$179K ﹤0.01% 4580
2023
Q2 		$1.46M Sell
71,618
-27,012
-27% -$548K ﹤0.01% 4613
2023
Q1 		$2.15M Buy
98,630
+2,714
+3% +$66K ﹤0.01% 4424
2022
Q4 		$2.97M Sell
95,916
-11,652
-11% -$329K ﹤0.01% 4175
2022
Q3 		$2.74M Sell
107,568
-39,087
-27% -$916K ﹤0.01% 4206
2022
Q2 		$2.98M Buy
146,655
+41,664
+40% +$923K ﹤0.01% 4219
2022
Q1 		$2.6M Buy
104,991
+32,264
+44% +$976K ﹤0.01% 4318
2021
Q4 		$2.53M Buy
72,727
+781
+1% +$24.8K ﹤0.01% 4394
2021
Q3 		$1.95M Sell
71,946
-89,729
-55% -$2.28M ﹤0.01% 4604
2021
Q2 		$4.19M Buy
161,675
+2,136
+1% +$51.2K ﹤0.01% 3968
2021
Q1 		$3.44M Buy
159,539
+137,996
+641% +$3.48M ﹤0.01% 3792
2020
Q4 		$463K Buy
21,543
+14,093
+189% +$342K ﹤0.01% 5123
2020
Q3 		$109K Sell
7,450
-11,946
-62% -$216K ﹤0.01% 5386
2020
Q2 		$434K Sell
19,396
-484,698
-96% -$8.86M ﹤0.01% 4673
2020
Q1 		$7.12M Sell
504,094
-544,171
-52% -$8.25M ﹤0.01% 2104
2019
Q4 		$17M Buy
1,048,265
+843,306
+411% +$19.9M ﹤0.01% 1806
2019
Q3 		$7.17M Buy
204,959
+193,096
+1,628% +$9.19M ﹤0.01% 2475
2019
Q2 		$670K Buy
11,863
+784
+7% +$56.5K ﹤0.01% 4450
2019
Q1 		$809K Sell
11,079
-144,453
-93% -$9.97M ﹤0.01% 4253
2018
Q4 		$9.92M Buy
155,532
+121,669
+359% +$9.05M ﹤0.01% 2141
2018
Q3 		$3.38M Sell
33,863
-7,209
-18% -$598K ﹤0.01% 3570
2018
Q2 		$2.92M Buy
41,072
+3,523
+9% +$296K ﹤0.01% 3726
2018
Q1 		$3.91M Sell
37,549
-285,845
-88% -$32.2M ﹤0.01% 3306
2017
Q4 		$32.6M Buy
323,394
+307,782
+1,971% +$22.7M 0.01% 1267
2017
Q3 		$546K Buy
15,612
+10,548
+208% +$285K ﹤0.01% 4827
2017
Q2 		$121K Sell
5,064
-6,096
-55% -$153K ﹤0.01% 5562
2017
Q1 		$310K Buy
+11,160
New +$260K ﹤0.01% 5099

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Morgan Stanley's ANAB Position: Q2 2026 in Review

Morgan Stanley reduced its AnaptysBio (ANAB) stake by 74% in Q2 2026, selling an estimated $44.7M and leaving 257,091 shares worth $17.4M. The position accounts for ﹤0.01% of the portfolio, ranked #3222.

Morgan Stanley first reported a position in ANAB in Q1 2017 and has held it in 38 quarters since. The position peaked at $55.1M in Q1 2026. 213 funds tracked by Wall St. Rank hold ANAB as of Q2 2026.

  • Morgan Stanley held 257,091 shares of AnaptysBio worth $17.4M as of Q2 2026.
  • Morgan Stanley sold 736,814 AnaptysBio shares in Q2 2026, an estimated $44.7M.
  • AnaptysBio made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #3222 holding.
  • Morgan Stanley first reported a position in AnaptysBio in Q1 2017 and has held it in 38 quarters since.
  • Morgan Stanley's AnaptysBio position peaked at $55.1M in Q1 2026.
  • 213 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.